← board
EQ
Equilliumdistress 3/10 · well-funded / low risk$2.760%today-14% from 52w high
Lead: Graft Versus Host Disease
Revenue
$41M
Liquidity
$61M
Runway
3.3 yrs
Shares 1y
+6%
Price & events
+133.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+10.4%
1W
-2.8%
1M
+27.2%
3M
+117.3%
6M
+573.2%
1Y
+217.2%
2Y
-49.0%
5Y
-45.1%
All
Overview
- Market Cap
- $174.51M
- Volume
- 37.66K
- 52 Week Range
- $0.35 – $3.20
- Total Shares
- 63.23M
- Float Shares
- 35.44M
- Short %
- 9.38%
- % Held by Insiders
- 16.05%
- % Held by Institutions
- 64.31%
- RVOL
- 0.05x
- Beta
- 1.77
Pipeline stages · 1 programs
Itolizumab, EQ001 Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-22 | Phase 3 | Itolizumab, EQ001 Placeboorphanfast track | Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD | 158 | terminated |
Catalyst news & presentations · 5
- 2025-09-30withdrawalitolizumab · Collaboration and license agreement terminated, rights to itolizumab reverted to BioconSEC 8-K
- 2025-08-29fda agreementRegained compliance with Nasdaq minimum bid price requirement.SEC 8-K
- 2025-08-03fda agreementAmended ATM agreement, changed sales agent to LifeSci Capital LLCSEC 8-K
- first quarter of 2025readoutPhase 2itolizumab · Topline data from Phase 2 study in ulcerative colitis.SEC 8-K
- 2024-10-30partnershipitolizumab · Ono option to acquire itolizumab rights lapsed; agreement terminated. Equillium retains all commercial rights.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+210% upside) · 9 analysts
- 2026-07-13Piper SandlerOverweight
- 2026-06-02Roth CapitalBuy
- 2026-05-28Leerink PartnersMarket Perform → Outperform
- 2026-05-28Roth CapitalBuy
- 2026-04-17Roth CapitalBuy
- 2026-04-16B. Riley SecuritiesBuy
Recent news
- 2026-07-22Equillium: The Market Seems To Have Already Priced In Phase 1 Success (NASDAQ:EQ) - Seeking Alpha
- 2026-07-22Clear Street initiates Equillium stock with buy rating on IBD drug potential - Investing.com UK
- 2026-07-21Clear Street initiates Equillium stock with buy rating on IBD drug potential - Investing.com Nigeria
- 2026-07-21Clear Street initiates Equillium stock with buy rating on IBD drug potential - Investing.com Canada
- 2026-07-14EQUILLIUM INC : PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $20 - webull.com
- 2026-07-13EQ Initiated Coverage by Piper Sandler - Rating Set to Overweigh - GuruFocus
- 2026-07-13Piper Sandler initiates Equillium stock with overweight rating - Investing.com
- 2026-07-10ETFs Investing in Equillium, Inc. Stocks - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.